Outcomes of clinical pharmacists' recommendations on prescribing of oral H2 antagonists

Kelly Rogers, G. L. Johnson, D. M. White, D. M. Becker

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We evaluated the effectiveness and outcomes of clinical pharmacists' recommendations on oral H2 antagonist prescribing. One hundred patients were randomized to the intervention or control groups. The intervention group received a recommendation for therapeutic interchange of the least expensive H2 antagonist, dosage reduction, or discontinuation. Those accepted were reviewed to determine efficacy and tolerability of the new H2 antagonist. A questionnaire was sent to physicians who did not accept the recommendation. A 56% recommendation acceptance rate and a projected $8,400 annual cost savings to the outpatient clinics were calculated. We report 92% efficacy (lack of symptoms) and 100% tolerability (lack of adverse drug effects) with follow- up. The most common reasons physicians did not accept the recommendations were failure to see the recommendation form (41%) or oversight (32%). A chart recommendation was moderately effective in changing prescribing habits. Changing to nizatidine, decreasing the dose, or discontinuing the H2 antagonist did not clinically affect the patient's outcome of efficacy or tolerability. This study resulted in a remodeling of the intervention process for clinical pharmacists in the clinics and a therapeutic interchange program for all H2 antagonists.

Original languageEnglish (US)
JournalHospital Pharmacy
Volume33
Issue number9
StatePublished - Dec 1 1998
Externally publishedYes

Fingerprint

Interchanges
Pharmacists
Nizatidine
Physicians
Cost Savings
Ambulatory Care Facilities
Habits
Control Groups
Therapeutics
Pharmaceutical Preparations
Costs
Surveys and Questionnaires

All Science Journal Classification (ASJC) codes

  • Pharmacy
  • Pharmacology
  • Pharmacology (medical)

Cite this

Outcomes of clinical pharmacists' recommendations on prescribing of oral H2 antagonists. / Rogers, Kelly; Johnson, G. L.; White, D. M.; Becker, D. M.

In: Hospital Pharmacy, Vol. 33, No. 9, 01.12.1998.

Research output: Contribution to journalArticle

Rogers, Kelly ; Johnson, G. L. ; White, D. M. ; Becker, D. M. / Outcomes of clinical pharmacists' recommendations on prescribing of oral H2 antagonists. In: Hospital Pharmacy. 1998 ; Vol. 33, No. 9.
@article{f38d9dfbb806472590ca961c389a364d,
title = "Outcomes of clinical pharmacists' recommendations on prescribing of oral H2 antagonists",
abstract = "We evaluated the effectiveness and outcomes of clinical pharmacists' recommendations on oral H2 antagonist prescribing. One hundred patients were randomized to the intervention or control groups. The intervention group received a recommendation for therapeutic interchange of the least expensive H2 antagonist, dosage reduction, or discontinuation. Those accepted were reviewed to determine efficacy and tolerability of the new H2 antagonist. A questionnaire was sent to physicians who did not accept the recommendation. A 56{\%} recommendation acceptance rate and a projected $8,400 annual cost savings to the outpatient clinics were calculated. We report 92{\%} efficacy (lack of symptoms) and 100{\%} tolerability (lack of adverse drug effects) with follow- up. The most common reasons physicians did not accept the recommendations were failure to see the recommendation form (41{\%}) or oversight (32{\%}). A chart recommendation was moderately effective in changing prescribing habits. Changing to nizatidine, decreasing the dose, or discontinuing the H2 antagonist did not clinically affect the patient's outcome of efficacy or tolerability. This study resulted in a remodeling of the intervention process for clinical pharmacists in the clinics and a therapeutic interchange program for all H2 antagonists.",
author = "Kelly Rogers and Johnson, {G. L.} and White, {D. M.} and Becker, {D. M.}",
year = "1998",
month = "12",
day = "1",
language = "English (US)",
volume = "33",
journal = "Hospital Pharmacy",
issn = "0018-5787",
publisher = "Facts and Comparisons",
number = "9",

}

TY - JOUR

T1 - Outcomes of clinical pharmacists' recommendations on prescribing of oral H2 antagonists

AU - Rogers, Kelly

AU - Johnson, G. L.

AU - White, D. M.

AU - Becker, D. M.

PY - 1998/12/1

Y1 - 1998/12/1

N2 - We evaluated the effectiveness and outcomes of clinical pharmacists' recommendations on oral H2 antagonist prescribing. One hundred patients were randomized to the intervention or control groups. The intervention group received a recommendation for therapeutic interchange of the least expensive H2 antagonist, dosage reduction, or discontinuation. Those accepted were reviewed to determine efficacy and tolerability of the new H2 antagonist. A questionnaire was sent to physicians who did not accept the recommendation. A 56% recommendation acceptance rate and a projected $8,400 annual cost savings to the outpatient clinics were calculated. We report 92% efficacy (lack of symptoms) and 100% tolerability (lack of adverse drug effects) with follow- up. The most common reasons physicians did not accept the recommendations were failure to see the recommendation form (41%) or oversight (32%). A chart recommendation was moderately effective in changing prescribing habits. Changing to nizatidine, decreasing the dose, or discontinuing the H2 antagonist did not clinically affect the patient's outcome of efficacy or tolerability. This study resulted in a remodeling of the intervention process for clinical pharmacists in the clinics and a therapeutic interchange program for all H2 antagonists.

AB - We evaluated the effectiveness and outcomes of clinical pharmacists' recommendations on oral H2 antagonist prescribing. One hundred patients were randomized to the intervention or control groups. The intervention group received a recommendation for therapeutic interchange of the least expensive H2 antagonist, dosage reduction, or discontinuation. Those accepted were reviewed to determine efficacy and tolerability of the new H2 antagonist. A questionnaire was sent to physicians who did not accept the recommendation. A 56% recommendation acceptance rate and a projected $8,400 annual cost savings to the outpatient clinics were calculated. We report 92% efficacy (lack of symptoms) and 100% tolerability (lack of adverse drug effects) with follow- up. The most common reasons physicians did not accept the recommendations were failure to see the recommendation form (41%) or oversight (32%). A chart recommendation was moderately effective in changing prescribing habits. Changing to nizatidine, decreasing the dose, or discontinuing the H2 antagonist did not clinically affect the patient's outcome of efficacy or tolerability. This study resulted in a remodeling of the intervention process for clinical pharmacists in the clinics and a therapeutic interchange program for all H2 antagonists.

UR - http://www.scopus.com/inward/record.url?scp=0032471934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032471934&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0032471934

VL - 33

JO - Hospital Pharmacy

JF - Hospital Pharmacy

SN - 0018-5787

IS - 9

ER -